VIENNA, Sept 17 (Reuters) - Eli Lilly's (LLY.N), opens new tab bid for approval for an experimental weight-loss pill got a boost on Wednesday with new clinical trial data, and the company reaffirmed ...

VIENNA (Reuters) - Eli Lilly's bid for approval for an experimental weight-loss pill got a boost on Wednesday with new clinical trial data, and the company reaffirmed that it was too soon to assume ...

i Controlled for family-wise type 1 error rate. ii Percentage of participants achieving body weight reductions of ≥20% with orforglipron 6 mg was not controlled for ...

The U.S. Food and Drug Administration (FDA) has determined that a promotional video featuring Zepbound and Mounjaro (tirzepatide), both produced by Eli Lilly And Co. (NYSE:LLY), is false or misleading ...

Eli Lilly & Co.’s obesity pill prompted enough weight loss in a large clinical trial to be meaningful for patients and have far-reaching implications for the field, doctors said. The US drugmaker’s ...

Eli Lilly’s experimental weight-loss pill could be fast-tracked under a one- to two-month review process recently launched by the U.S. Food and Drug Administration, several Wall Street analysts said.

Eli Lilly has built a track record of growth thanks to a wide variety of drugs, but one portfolio in particular may drive gains a few years from now. The company already is a leader in the weight-loss ...

With a background in journalism and counseling, Penny Min blends analytical research with real-world insight to help readers make informed financial decisions. At Forbes Marketplace, she specializes ...

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them. This edge has propelled Lilly to the forefront, with ...

Drugmaker Eli Lilly says its daily oral GLP-1 pill may help people who have obesity and people with Type 2 diabetes lose approximately 23 pounds or more than 10% of their body weight on average, ...